BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study

Abstract: High-dose cytarabine is the backbone of acute myeloid leukemia (AML) treatment. Nevertheless, its use in older patients is considerably limited due to increased toxicity. BST-236 (INN aspacytarabine) is a novel cytarabine prodrug designed to deliver high-dose cytarabine to target cells wit...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Tsila Zuckerman, Ron Ram, Luiza Akria, Maya Koren-Michowitz, Ron Hoffman, Israel Henig, Noa Lavi, Yishai Ofran, Netanel A. Horowitz, Olga Nudelman, Sigal Tavor, Shay Yeganeh, Stela Gengrinovitch, Liat Flaishon, Shoshi Tessler, Ruth Ben Yakar, Jacob M. Rowe
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2019-11-01
Edice:	Blood Advances
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2473952920317729
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!